Citation Information :
Vora M. Efficacy and Tolerability of Vortioxetine in Patients with Major Depressive Disorder: A Clinical Perspective from 33 Indian Cases. Ind J Priv Psychiatry 2020; 14 (2):57-61.
Aim: Limited data are available concerning the tolerability and efficacy of vortioxetine in Indian depressive patients. This retrospective prescription review analysis provides clinical experience of vortioxetine in patients with major depressive disorder (MDD) and high ratings of anxiety (anxious depression).
Materials and methods: This prescription data review was carried out at Westcoast Institute of Neuroscience, India. Data were extracted from prescription of all the patients suffering from depression and other psychiatric disorders who were treated with vortioxetine (Brintellix) from February 1, 2019, to May 31, 2020.
Results: Thirty-three prescription records were reviewed during the study. Vortioxetine improved depressive and psychological symptoms with minimum adverse effects. Vortioxetine showed good tolerability in majority of patients who were still receiving vortioxetine monotherapy by the end of the therapy. Mental Status Examination (MSE) revealed that the patients treated with vortioxetine demonstrated better orientation, reactiveness, and attentiveness.
Conclusion: This retrospective prescription review analysis demonstrated the effectiveness, and tolerability of vortioxetine in Indian MDD patients with depressive and anxiety symptoms.
Arvind BA, Gururaj G, Loganathan S, et al. Prevalence and socioeconomic impact of depressive disorders in India: multisite population-based cross-sectional study. BMJ Open 2019;9(6):e027250. DOI: 10.1136/bmjopen-2018-027250.
Ishak WW, Balayan K, Bresee C, et al. A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting. Qual Life Res 2013;22(3):585–596. DOI: 10.1007/s11136-012-0187-6.
Birnbaum HG, Kessler RC, Kelley D, et al. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety 2010;27(1):78–89. DOI: 10.1002/da.20580.
Olesen J, Gustavsson A, Svensson M, et al. The economic cost of brain disorders in Europe. Eur J Neurol 2012;19(1):155–162. DOI: 10.1111/j.1468-1331.2011.03590.x.
Gasse C, Petersen L, Chollet J, et al. Pattern and predictors of sick leave among users of antidepressants: a Danish retrospective register-based cohort study. J Affect Disord 2013;151(3):959–966. DOI: 10.1016/j.jad.2013.08.015.
Krol M, Papenburg J, Koopmanschap M, et al. Do productivity costs matter? Pharmacoeconomics 2011;29(7):601–619. DOI: 10.2165/11539970-000000000-00000.
Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003;183(6):514–519. DOI: 10.1192/bjp.183.6.514.
Ho N, Sommers MS, Lucki I. Effects of diabetes on hippocampal neurogenesis: links to cognition and depression. Neurosci Biobehav Rev 2013;37(8):1346–1362. DOI: 10.1016/j.neubiorev.2013.03.010.
Montgomery SA, Gommoll CP, Chen C, et al. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr 2015;20(2):148–156. DOI: 10.1017/S1092852914000273.
Pence BW, O'Donnell JK, Gaynes BN. The depression treatment cascade in primary care: a public health perspective. Curr Psychiatry Rep 2012;14(4):328–335. DOI: 10.1007/s11920-012-0274-y.
Ansseau M, Demyttenaere K, Heyrman J, et al. Objective: remission of depression in primary care The Oreon Study. Eur Neuropsychopharmacol 2009;19(3):169–176. DOI: 10.1016/j.euroneuro. 2008.10.003.
Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015;145:43–57. DOI: 10.1016/j.pharmthera.2014.07.001.
Baldwin DS, Florea I, Jacobsen PL, et al. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord 2016;206:140–150. DOI: 10.1016/j.jad.2016.07.015.
Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14(1):276. DOI: 10.1186/s12888-014-0276-x.
Thase ME, Mahableshwarkar AR, Dragheim M, et al. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol 2016;26(6):979–993. DOI: 10.1016/j.euroneuro.2016.03.007.
Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opin Drug Discov 2019;14(1):81–89. DOI: 10.1080/17460441.2019.1546691.
Koesters M, Ostuzzi G, Guaiana G, et al. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. DOI: 10.1136/bmjopen-2018-027250.
Kessler RC, Sampson NA, Berglund P, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci 2015;24(3):210–226. DOI: 10.1017/S2045796015000189.
Clevenger SS, Malhotra D, Dang J, et al. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder. Ther Adv Psychopharmacol 2018;8(1):49–58. DOI: 10.1177/2045125317737264.
Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Safety 2015;14(8):1291–1304. DOI: 10.1517/14740338.2015.1046836.
Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014;68(1):60–82. DOI: 10.1111/ijcp.12350.
Jacobsen PL, Mahableshwarkar AR, Chen Y, et al. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med 2015;12(10):2036–2048. DOI: 10.1111/jsm.12980.
Liguori C, Ferini-Strambi L, Izzi F, et al. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol 2019;85(1):240–244. DOI: 10.1111/bcp.13772.
Cao B, Park C, Rosenblat JD, et al. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial. J Psychopharmacol 2019;33(11):1388–1394. DOI: 10.1177/0269881119874485.
Christensen MC, Florea I, Lindsten A, et al. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32(10):1086–1097. DOI: 10.1177/0269881118788826.
Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 2015;40(8):2025–2037. DOI: 10.1038/npp.2015.52.
McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17(10):1557–1567. DOI: 10.1017/S1461145714000546.
Subramaniapillai M, Mansur RB, Zuckerman H, et al. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. Compr Psychiatry 2019;94:152113. DOI: 10.1016/j.comppsych.2019.07.006.